



## Host-Pathogen Interactions and Monoclonal Antibody Therapeutics

Guest Editors:

**Dr. Giuseppe A. Sautto**

Cleveland Clinic Florida Research  
and Innovation Center, Port St.  
Lucie, FL 34987, USA

**Dr. Roberta Antonia Diotti**

Microbiology and Virology  
Laboratory, Vita-Salute  
University, San Raffaele, 20132  
Milan, Italy

Deadline for manuscript  
submissions:

**15 August 2024**

### Message from the Guest Editors

Since the description of the first reliable methodology for developing monoclonal antibodies (mAbs) by Köhler and Milstein in 1975 using the hybridoma technique, tremendous advances in their generation, characterization, engineering and expression have been made.

The hybridoma methodology is still used today by several investigators, but new technologies have been developed and described. These new technologies have further increased the importance of mAbs even today, especially during the SARS-CoV-2 pandemic, where a plethora of SARS-CoV-2-specific mAbs have been reported in the literature as potential therapeutic tools.

Suggested topics for this Special Issue include, but are not limited to, new mAbs against infectious pathogens, the host immune response, the identification of potential viral antigens and epitopes, and new techniques for mAb discovery, development, production and engineering. There is no limitation on the type of contribution; original articles, brief communications, case reports, and reviews are all welcome. Your valuable input will enrich the current state of knowledge and contribute to the control of infectious diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Lawrence S. Young

Warwick Medical School,  
University of Warwick, Coventry  
CV4 7AL, UK

## Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

**Journal Rank:** JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

## Contact Us

---

*Pathogens* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pathogens](http://mdpi.com/journal/pathogens)  
[pathogens@mdpi.com](mailto:pathogens@mdpi.com)  
[X@Pathogens\\_MDPI](https://twitter.com/Pathogens_MDPI)